Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 2
1992 3
1993 1
1994 4
1998 1
2000 1
2001 3
2002 3
2003 2
2004 11
2005 9
2006 9
2007 12
2008 15
2009 12
2010 14
2011 10
2012 12
2013 9
2014 16
2015 13
2016 18
2017 20
2018 19
2019 19
2020 18
2021 23
2022 24
2023 21
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Results by year

Filters applied: . Clear all
Page 1
Psoriatic Arthritis.
Ritchlin CT, Colbert RA, Gladman DD. Ritchlin CT, et al. N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557. N Engl J Med. 2017. PMID: 28273019 Review. No abstract available.
Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry.
Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabechian D, Hughes LB, Salomon-Escoto K, Watts GFM, Jonsson AH, Rangel-Moreno J, Meednu N, Rozo C, Apruzzese W, Eisenhaure TM, Lieb DJ, Boyle DL, Mandelin AM 2nd; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium; Boyce BF, DiCarlo E, Gravallese EM, Gregersen PK, Moreland L, Firestein GS, Hacohen N, Nusbaum C, Lederer JA, Perlman H, Pitzalis C, Filer A, Holers VM, Bykerk VP, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S. Zhang F, et al. Nat Immunol. 2019 Jul;20(7):928-942. doi: 10.1038/s41590-019-0378-1. Epub 2019 May 6. Nat Immunol. 2019. PMID: 31061532 Free PMC article.
Psoriatic arthritis from a mechanistic perspective.
Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Schett G, et al. Among authors: ritchlin c. Nat Rev Rheumatol. 2022 Jun;18(6):311-325. doi: 10.1038/s41584-022-00776-6. Epub 2022 May 5. Nat Rev Rheumatol. 2022. PMID: 35513599 Review.
Notch signalling drives synovial fibroblast identity and arthritis pathology.
Wei K, Korsunsky I, Marshall JL, Gao A, Watts GFM, Major T, Croft AP, Watts J, Blazar PE, Lange JK, Thornhill TS, Filer A, Raza K, Donlin LT; Accelerating Medicines Partnership Rheumatoid Arthritis & Systemic Lupus Erythematosus (AMP RA/SLE) Consortium; Siebel CW, Buckley CD, Raychaudhuri S, Brenner MB. Wei K, et al. Nature. 2020 Jun;582(7811):259-264. doi: 10.1038/s41586-020-2222-z. Epub 2020 Apr 22. Nature. 2020. PMID: 32499639 Free PMC article.
Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems.
Castillo RL, Sidhu I, Dolgalev I, Chu T, Prystupa A, Subudhi I, Yan D, Konieczny P, Hsieh B, Haberman RH, Selvaraj S, Shiomi T, Medina R, Girija PV, Heguy A, Loomis CA, Chiriboga L, Ritchlin C, Garcia-Hernandez ML, Carucci J, Meehan SA, Neimann AL, Gudjonsson JE, Scher JU, Naik S. Castillo RL, et al. Among authors: ritchlin c. Sci Immunol. 2023 Jun 8;8(84):eabq7991. doi: 10.1126/sciimmunol.abq7991. Epub 2023 Jun 2. Sci Immunol. 2023. PMID: 37267384 Free PMC article.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ. McInnes IB, et al. Among authors: ritchlin ct. Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6. Lancet. 2023. PMID: 36493791 Free article. Clinical Trial.
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group. McInnes IB, et al. Among authors: ritchlin c. Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X. Lancet. 2020. PMID: 32386593 Clinical Trial.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT; DISCOVER-1 Study Group. Deodhar A, et al. Among authors: ritchlin ct. Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178765 Free article. Clinical Trial.
315 results